Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025

Reuters

2025/11/11

Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025

Inovio Pharmaceuticals Inc. reported a loss from operations of $21.2 million, or $0.41 per share, for the quarter ended September 30, 2025, compared to a loss of $27.3 million, or $0.97 per share, for the same quarter in 2024. As of September 30, 2025, Inovio held $50.8 million in cash, cash equivalents, and short-term investments, down from $94.1 million at the end of 2024. The company had 53.6 million common shares outstanding, with 94.5 million on a fully diluted basis. Inovio estimates its current cash resources will support operations into the second quarter of 2026. Key business developments include the completion of a rolling Biologics License Application submission for INO-3107, with priority review requested and potential FDA approval and launch targeted for mid-2026. Results from a Phase 1 trial of Inovio's DNA-Encoded Monoclonal Antibody technology were published in Nature Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH20551) on November 10, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582800325"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582800325\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582800325?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582800325","market":"us","top_or_hot":-1,"title":"Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Inovio Pharmaceuticals Inc. reported a loss from operations of $21.2 million, or $0.41 per share, for the quarter ended September 30, 2025, compared to a loss of $27.3 million, or $0.97 per share, for the same quarter in 2024. As of September 30, 2025, Inovio held $50.8 million in cash, cash equivalents, and short-term investments, down from $94.1 million at the end of 2024. The company had 53.6 million common shares outstanding, with 94.5 million on a fully diluted basis. Inovio estimates its current cash resources will support operations into the second quarter of 2026. Key business developments include the completion of a rolling Biologics License Application submission for INO-3107, with priority review requested and potential FDA approval and launch targeted for mid-2026. Results from a Phase 1 trial of Inovio's DNA-Encoded Monoclonal Antibody technology were published in Nature Medicine.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH20551) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Inovio Pharmaceuticals Inc. reported a loss from operations of $21.2 million, or $0.41 per share, for the quarter ended September 30, 2025, compared to a loss of $27.3 million, or $0.97 per share, for the same quarter in 2024. As of September 30, 2025, Inovio held $50.8 million in cash, cash equivalents, and short-term investments, down from $94.1 million at the end of 2024. The company had 53.6 million common shares outstanding, with 94.5 million on a fully diluted basis. Inovio estimates its current cash resources will support operations into the second quarter of 2026. Key business developments include the completion of a rolling Biologics License Application submission for INO-3107, with priority review requested and potential FDA approval and launch targeted for mid-2026. Results from a Phase 1 trial of Inovio's DNA-Encoded Monoclonal Antibody technology were published in Nature Medicine.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH20551) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7hpRzj:1","article_id":"2582800325","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582800325","pubTimestamp":1762808874,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Inovio Pharmaceuticals Inc. reported a loss from operations of $21.2 million, or $0.41 per share, for the quarter ended September 30, 2025, compared to a loss of $27.3 million, or $0.97 per share, for the same quarter in 2024. As of September 30, 2025, Inovio held $50.8 million in cash, cash equivalents, and short-term investments, down from $94.1 million at the end of 2024. The company had 53.6 million common shares outstanding, with 94.5 million on a fully diluted basis. Inovio estimates its current cash resources will support operations into the second quarter of 2026. Key business developments include the completion of a rolling Biologics License Application submission for INO-3107, with priority review requested and potential FDA approval and launch targeted for mid-2026. Results from a Phase 1 trial of Inovio's DNA-Encoded Monoclonal Antibody technology were published in Nature Medicine.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","BK4139":"生物科技","INO":"伊诺维奥制药","BK4568":"美国抗疫概念"},"translate_title":"Inovio Pharmaceuticals公布2025年第三季度运营亏损2120万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":0.9},"content_text":"Inovio Pharmaceuticals posts $21.2 million operating loss for Q3 2025\n    \n\n        Inovio Pharmaceuticals Inc. reported a loss from operations of $21.2 million, or $0.41 per share, for the quarter ended September 30, 2025, compared to a loss of $27.3 million, or $0.97 per share, for the same quarter in 2024. As of September 30, 2025, Inovio held $50.8 million in cash, cash equivalents, and short-term investments, down from $94.1 million at the end of 2024. The company had 53.6 million common shares outstanding, with 94.5 million on a fully diluted basis. Inovio estimates its current cash resources will support operations into the second quarter of 2026. Key business developments include the completion of a rolling Biologics License Application submission for INO-3107, with priority review requested and potential FDA approval and launch targeted for mid-2026. Results from a Phase 1 trial of Inovio's DNA-Encoded Monoclonal Antibody technology were published in Nature Medicine.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH20551) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}